Latest News

By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...

If you are wondering whether Open Text is attractively priced today, the recent share moves and current valuation score give you a lot to work with. The stock closed at US$28.80, with a 13.0% decline over the last 7 days and a 13.7% decline over the last 30 days, while the 1 year return stands at 5.3% and the 5 year return at 29.3% decline. These price moves sit against a backdrop of ongoing attention on large software providers and their ability to keep delivering reliable cash flows and...

BXP has completed more than $1.0b of property sales, including residential, land, and non core office assets. The transactions occurred across several key gateway markets as part of a multi year portfolio optimization plan. These sales contribute to BXP's progress toward its $1.9b asset disposition target for 2025 to 2027. For investors watching NYSE:BXP, the latest $1.0b plus in completed property sales comes at a time when the stock trades around $65.63. Recent share performance has been...

If you are wondering whether Macquarie Group at around A$206.97 is offering fair value or a potential mispricing right now, this article breaks down what the numbers are actually saying about the stock. The share price has returned 0.7% over the last 7 days, 3.2% over 30 days, 1.6% year to date, with a 9.9% decline over 1 year. The 3 year and 5 year returns stand at 24.7% and 80.3% respectively. Recent coverage has focused on how Macquarie Group is being viewed as a key player among...

D.R. Horton (DHI) opened fiscal Q1 2026 with revenue of US$6.9b and basic EPS of US$2.03, putting a fresh quarterly snapshot alongside a trailing twelve month EPS of US$11.07 on revenue of US$33.5b and net income of US$3.3b. Over the past year, the company has seen quarterly revenue range from US$7.6b to US$10.0b and basic EPS move between US$2.03 and US$3.95, giving investors a clear view of how the current print sits within recent trading conditions and setting the stage for a closer look...

If you are wondering whether Blue Bird's current share price still offers value, the key question is how the market is weighing its recent performance against what the business could justify over time. The stock last closed at US$49.08, with returns of 0.3% over the past week, a 5.1% decline over 30 days, a 5.0% gain year to date and 16.7% over the last year, plus a very large return over three years and a 127.4% gain over five years. Recent headlines around Blue Bird have focused on the...

PetroTal Corp. recently issued its 2026 guidance, targeting average production of 11,750–12,250 barrels of oil per day, resuming Bretaña field drilling with a third-party contractor, and suspending dividends while maintaining at least US$60,000,000 of unrestricted cash. The appointment of veteran operator Jorge Osorio as Chief Operating Officer, with decades of upstream experience at Ecopetrol and BP, adds operational depth as PetroTal shifts toward stricter capital discipline and a phased...

Earlier in January 2026, Ocugen announced positive preliminary 12‑month Phase 2 ArMaDa data for OCU410 in geographic atrophy secondary to dry age‑related macular degeneration, showing reduced lesion growth and favorable safety across evaluated patients. An interesting highlight is that medium doses produced greater lesion growth reduction than high doses, and no serious OCU410‑related adverse events were reported in either Phase 1 or Phase 2 so far. Next, we’ll assess how this early OCU410...

AvalonBay Communities, NYSE:AVB, has released the final tax treatment classification for its 2025 dividend distributions. The update details how different portions of the 2025 dividends will be categorized for tax purposes under current regulations. The announcement gives existing and prospective shareholders clearer information for tax planning around AVB’s upcoming payouts. AvalonBay Communities, NYSE:AVB, is putting hard numbers around its 2025 dividend tax classifications at a time...

Key Insights The projected fair value for Vantage Towers is €43.26 based on Dividend Discount Model With €38.20 share...

As the Middle East market shows resilience with most Gulf markets gaining ahead of earnings and Dubai reaching its strongest level in nearly two decades, investors are keenly observing how upcoming fourth-quarter reports might influence sentiment. Amidst this backdrop, identifying promising stocks involves looking for companies with strong fundamentals and growth potential that can thrive even as oil price volatility and cautious investor sentiment persist.

Elekta (OM:EKTA B) has attracted fresh attention after its Elekta Evo CT-Linac received FDA 510(k) clearance, opening the door for U.S. adoption of its AI supported imaging and radiation therapy platform. See our latest analysis for Elekta. The FDA clearance arrives at a time when Elekta’s share price has a 90 day share price return of 20.20% and a 30 day share price return of 6.47%, while the 1 year total shareholder return of a 2.89% decline and 5 year total shareholder return of a 40%...

If you are wondering whether Fortune Brands Innovations is offering value at its current share price, this article walks through what the numbers are really saying about the stock. The share price recently closed at US$58.98, with a 15.6% return over the last 30 days but a 19.2% decline over the past year, which can change how investors view both its potential and its risk. Recent news around the company has focused on its positioning within the capital goods sector and how investors are...

If you are wondering whether Graphic Packaging Holding is trading at an attractive price today, the key question is whether the current share price properly reflects the value of its business. The stock last closed at US$14.79, with returns of a 4.9% decline over 7 days, a 4.1% decline over 30 days, a 2.4% decline year to date, a 46.6% decline over 1 year, a 32.0% decline over 3 years, and a 3.4% decline over 5 years. These moves have kept valuation on many investors' radar, especially as...

If you are wondering whether Acadia Healthcare Company stock is priced attractively right now, you are not alone. Recent moves have put valuation firmly in the spotlight. The share price recently closed at US$14.24, with a 13.5% gain over the last 7 days, a 1.2% decline over 30 days, a 0.3% decline year to date, and longer term returns of a 67.9% decline over 1 year, an 83.1% decline over 3 years, and a 72.1% decline over 5 years. Recent coverage of Acadia Healthcare Company has focused on...

Papa John’s International recently reported a quarter with flat year-on-year revenue that fell short of analyst expectations, alongside a miss on full-year EBITDA guidance and revenue estimates. At the same time, the company is experimenting with wellness-oriented innovation through a one-day, protein-infused crust pizza trial for Papa Rewards members at a single Atlanta location. Next, we’ll explore how the earnings miss and cautious analyst sentiment may influence Papa John’s investment...

If you are wondering whether Rolls-Royce Holdings shares still offer value after a strong run, the key question now is how the current price compares with what the underlying business might be worth. The stock closed at £12.81, with a 7 day return of a 1.8% decline, a 30 day return of 9.5% and a 1 year return of 118.4%. This naturally has investors asking whether the recent performance reflects lasting change or simply shifting sentiment. Recent headlines have focused on Rolls-Royce as a...

AtaiBeckley (NasdaqGM: ATAI) completed key Phase 2b and open label studies for BPL-003 in treatment resistant depression with robust outcomes. The company redomiciled to the US and was added to the NASDAQ Biotechnology Index, aligning its structure with a US investor base. AtaiBeckley raised $300 million to fund late stage clinical programs and entered a new partnership with Beckley Psytech. For investors tracking mental health therapeutics, AtaiBeckley now sits at an interesting junction,...

It is hard to get excited after looking at AAC Technologies Holdings' (HKG:2018) recent performance, when its stock has...

Porsche Automobil Holding (XTRA:PAH3) is scheduled to present at the 25th German Corporate Conference in Frankfurt on January 20, 2026. Chief Financial Officer and IT Officer Johannes Lattwein will address investors. See our latest analysis for Porsche Automobil Holding. At a share price of €35.64, Porsche Automobil Holding has had a weak near term patch, with a 30 day share price return of 10.9% and a year to date decline of 11.96%. The 1 year total shareholder return of 1.34% and 3 year...

If you are wondering whether Inspire Medical Systems is attractively priced today, this article walks through what the current share price might be implying about the business. The stock last closed at US$94.45, with returns of 2.2% over the past week, a 2.2% decline over 30 days, a 2.4% gain year to date, and declines of 49.0% over 1 year, 62.1% over 3 years, and 53.1% over 5 years. These mixed returns have put more attention on what is actually baked into the current valuation and how the...

Omnicom Group (NYSE:OMC) has launched the next generation of its Omni marketing intelligence platform. The updated platform integrates recent acquisitions, AI tools, and data infrastructure into a single system for clients. The move reflects Omnicom’s focus on a unified, AI-driven marketing ecosystem across strategy, creative, and performance. Omnicom Group operates as a global marketing and communications company, and Omni sits at the center of how it connects media, creative, and data for...

If you are wondering whether Booz Allen Hamilton Holding is attractively priced right now, the stock's recent moves and valuation checks give you a lot to work with. The share price recently closed at US$93.46, with a 9.6% gain over the last 30 days, a 10.1% return year to date and a 33.0% decline over the past year. Recent coverage has focused on how Booz Allen sits within the commercial services space and how investors are reassessing companies linked to government and consulting work...

Earlier in January 2026, Biohaven reported encouraging early clinical experience from its proprietary MoDE™ and TRAP™ extracellular protein degrader platforms, showing rapid removal of disease-causing proteins and associated clinical improvements in IgA nephropathy and Graves’ disease, alongside continued progress in its broader neurology and rare disease pipeline. The company also used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to spotlight these first-in-class...